article thumbnail

When Worlds Collide: The Theory of Real-World Evidence Meets Reality

The FDA Law Blog

Further, FDA has stated that enabling advanced data analytics, including RWD, is one of the objectives incorporated in the FDA’s Information Technology Strategy for FY 2024-2027. This guidance, when finalized, will replace the original version of this document finalized in 2017.

FDA 111
article thumbnail

ISPE Represented at PIC/S 50th Anniversary Event

ISPE

Some of the highlights of the presentations given during the Symposium were as follows: The PIC/S Chairperson, Paul Gustafson, Health Canada, presented on PIC/S’ new strategic plan for 2023-2027 which covered the following elements: Promote, improve and monitor inspection reliance amongst PIC/S member authorities.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Update on CDER, CBER, and CDRH Meetings with Industry

The FDA Law Blog

It is also crucial to maintain a respectful and cooperative demeanor, document the meeting discussion and action items, and promptly address follow-up actions. FDA notes that all in-person FTF formal meetings at CDER and CBER will have a hybrid component (virtual attendees in addition to in-person attendees).

FDA 53
article thumbnail

Supreme court throws Novartis a lifeline for Gilenya defense

pharmaphorum

The latest judgments relate to an attempt by Chinese drugmaker HEC Pharma to bring a generic version of fingolimod to market in the US, and Novartis defense of the 9,187, 405 patent which expires in December 2027.

article thumbnail

Wearables, Sensors, and Apps Part 1 – Updates on FDA’s PDUFA VII Goals for the Use of Digital Health Technologies in Drug and Biological Product Development

The FDA Law Blog

This blog provides an update on the DHT-related PDUFA VII goals that were targeted for completion in the first two quarters of FDA’s Fiscal Year (FY) 2023, including: By the end of Q2 FY 2023, FDA will establish a DHT framework document to guide the use of DHT-derived data in regulatory decision-makings for drugs and biological products.

FDA 52
article thumbnail

Pre-Filled Syringes East Coast 2022

pharmaphorum

million in 2020 and with the rapid growth of the industry, is expected to grow at a CAGR of 8.95% up to 2027. Understand requirements to facilitate the documentation preparation needed to obtain a NB Opinion. Device innovations, connected delivery and regulatory guidance for advanced parenteral systems. 13.00 – 17.00.

article thumbnail

What can Rishi Sunak do for the UK’s pharma industry

Pharmaceutical Technology

At the time of its publication, the document prioritised the finalisation of Brexit above all else. of gross domestic product (GDP) in R&D by 2027. In a more recent report, the ABPI found that the number of Phase III industry trials fell by 48% between 2017 and 2021.